Avalo Therapeutics (AVTX) news
Recent news
Avalo Therapeutics - selling stockholders may sell up to 128,189 shares of common stock - SEC filing
Avalo Therapeutics, Inc. (NASDAQ: AVTX) has announced a public offering of its common stock and pre-funded warrants to purchase shares of its common stock. The offering is being conducted under a shelf registration statement on Form S-3, which was filed with the U.S. Securities and Exchange…
AInvest Wire · Jul 28, 2026Avalo Therapeutics Inc: Leerink Partners initiates coverage with outperform rating; target price $38
Leerink Partners has initiated coverage of Avalo Therapeutics Inc (NASDAQ: AVLO) with an "outperform" rating and a target price of $38 per share. The firm's decision follows a series of recent financing activities led by Avalo, including a $125 million follow-on offering in February 2023 and a $150…
AInvest Wire · Jul 6, 2026Avalo Therapeutics appoints Ron Philip to board of directors
AInvest Wire · Jun 23, 2026ImportantAvalo Therapeutics announces 1-for-240 reverse stock split
Avalo Therapeutics announces 1-for-240 reverse stock split Avalo Therapeutics, a biopharmaceutical company, announced on July 6, 2022, that it will be implementing a one-for-twelve reverse stock split of its common stock [1]. This move aims to increase the per share price of its common stock to…
AInvest Wire · Dec 27, 2023ImportantAvalo Therapeutics shares surge 29% in premarket trading as Co. plans to sell 800 Series programs to AUG Therapeutics.
AInvest Wire · Sep 14, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.